Moderna 2022 Priorities and Capital Allocation
Our Phase 3 pipeline could lead to three respiratory commercial launches over the
next two to three years; will share proof-of-concept readouts in therapeutics in 2022
Vaccines in Phase 3:
.
Omicron-containing bivalent COVID booster ongoing in Phase 2/3 studies; mRNA-1273.214 bivalent booster vaccine
(wild-type and Omicron variant) is our lead candidate for Fall 2022
Flu vaccine (mRNA-1010) Phase 3 immunogenicity study expected to start in 2Q 2022
RSV vaccine (mRNA-1345) ongoing in a pivotal Phase 3 study, Conquer RSV
.
CMV vaccine (mRNA-1647) ongoing in a pivotal Phase 3 study, CMVictory
.
Proof-of-concept readouts in therapeutic modalities:
PA (mRNA-3927) ongoing in Phase 1/2 study (Paramount study). First cohort is fully enrolled and we are enrolling
patients into additional cohorts. All five patients eligible for the Open Label Extension (OLE) study have elected to
participate
MMA (mRNA-3705) ongoing in Phase 1/2 study (Landmark study). First cohort is fully enrolled and we are enrolling
patients into additional cohorts. One patient eligible to participate in the OLE study has elected to participate
PCV vaccine (mRNA-4157) ongoing in a Phase 2 study (PCV + Keytruda vs. Keytruda alone)
Slide 6
modernaView entire presentation